OFI Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

OFI Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$51K	Buy	946 +300	+46%	+$18.2K	﹤0.01%	1588
2015 Q2	$41K	Sell	646 -122	-16%	-$6.66K	﹤0.01%	1598
2015 Q1	$37K	Sell	768 -59	-7%	-$2.26K	﹤0.01%	1619
2014 Q4	$27K	Buy	827 +45	+6%	+$1.46K	﹤0.01%	1652
2014 Q3	$23K	Buy	782 +170	+28%	+$5.64K	﹤0.01%	1648
2014 Q2	$24K	Buy	612 +176	+40%	+$7.14K	﹤0.01%	1635
2014 Q1	$18K	Sell	436 -164	-27%	-$6.84K	﹤0.01%	1660
2013 Q4	$20K	Buy	+600	New	+$19.5K	﹤0.01%	1664

Other funds holding LGND

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OFI Advisors's LGND Position: Q3 2015 in Review

OFI Advisors increased its Ligand Pharmaceuticals (LGND) stake by 46% in Q3 2015, buying an estimated $18.2K and bringing the position to 946 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #1588.

OFI Advisors first reported a position in LGND in Q4 2013 and has held it in 8 quarters since. 203 funds tracked by Wall St. Rank hold LGND as of Q3 2015.

OFI Advisors held 946 shares of Ligand Pharmaceuticals worth $51K as of Q3 2015.
OFI Advisors bought 300 Ligand Pharmaceuticals shares in Q3 2015, an estimated $18.2K.
Ligand Pharmaceuticals made up ﹤0.01% of OFI Advisors's portfolio in Q3 2015, its #1588 holding.
OFI Advisors first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 8 quarters since.
203 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.